Table S2 from Expression of Adipocyte/Macrophage Fatty Acid–Binding Protein in Tumor-Associated Macrophages Promotes Breast Cancer Progression

Hao, Jiaqing; Yan, Fei; Zhang, Yuwen; Triplett, Ashley; Zhang, Ying; Schultz, Debra A.; Sun, Yanwen; Zeng, Jun; Silverstein, Kevin A.T.; Zheng, Qi; Bernlohr, David A.; Cleary, Margot P.; Egilmez, Nejat K.; Sauter, Edward; Liu, Shujun; Suttles, Jill; Li, Bing

doi:10.1158/0008-5472.22418462.v1

00085472can172465-sup-187857_3_supp_4531413_p3dv1n.docx (17.12 kB)

Table S2 from Expression of Adipocyte/Macrophage Fatty Acid–Binding Protein in Tumor-Associated Macrophages Promotes Breast Cancer Progression

journal contribution

posted on 2023-03-31, 01:42 authored by Jiaqing Hao, Fei Yan, Yuwen Zhang, Ashley Triplett, Ying Zhang, Debra A. Schultz, Yanwen Sun, Jun Zeng, Kevin A.T. Silverstein, Qi Zheng, David A. Bernlohr, Margot P. Cleary, Nejat K. Egilmez, Edward Sauter, Shujun Liu, Jill Suttles, Bing Li

Table S2 analyzes the association of A-FABP levels with breast cancer survival using TCGA dataset.

Funding

NIH

History

ARTICLE ABSTRACT

Tumor-associated macrophages (TAM) play a critical role in cancer development and progression. However, the heterogeneity of TAM presents a major challenge to identify clinically relevant markers for protumor TAM. Here, we report that expression of adipocyte/macrophage fatty acid–binding protein (A-FABP) in TAM promotes breast cancer progression. Although upregulation of A-FABP was inversely associated with breast cancer survival, deficiency of A-FABP significantly reduced mammary tumor growth and metastasis. Furthermore, the protumor effect of A-FABP was mediated by TAM, in particular, in a subset of TAM with a CD11b+F4/80+MHCII−Ly6C− phenotype. A-FABP expression in TAM facilitated protumor IL6/STAT3 signaling through regulation of the NFκB/miR-29b pathway. Collectively, our results suggest A-FABP as a new functional marker for protumor TAM.Significance: These findings identify A-FABP as a functional marker for protumor macrophages, thus offering a new target for tumor immunotherapy. Cancer Res; 78(9); 2343–55. ©2018 AACR.